Sanofi to Buy Bioverative for $11.6B

The transcript discusses Sanofi's acquisition of BIOVERATIV, a hemophilia drug maker, at a significant premium. The deal was unexpected as Sanofi had been focusing on oncology acquisitions. The acquisition aligns with Sanofi's strategy to expand in rare diseases. Despite the high cost, it is seen as a strategic move. The discussion also speculates on Sanofi's future acquisitions, including potential interest in Pfizer's OTC franchise.

What was the valuation of Bioverativ per share in the acquisition deal?

What challenges did Sanofi face in previous acquisitions mentioned in the text?

Why was the acquisition of Bioverativ considered a surprise?

What areas had Sanofi primarily focused on for acquisitions before this deal?

What potential future acquisition targets were mentioned for Sanofi?